サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：片頭痛治療薬の世界市場-2023-2030
市場調査レポート
商品コード
1279679

片頭痛治療薬の世界市場-2023-2030

Global Migraine Drugs Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
片頭痛治療薬の世界市場-2023-2030
出版日: 2023年05月26日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

片頭痛治療薬の世界市場は、2022年に40億3,580万米ドルに達し、2030年には97億9,110万米ドルに達し、有利な成長が予測されています。世界の片頭痛の増加、片頭痛とその治療法に関する意識の高まりにより、片頭痛治療薬市場は予測期間（2023-2030年）に12.1%のCAGRを示すと予想されます。また、安全で効果的な治療法に対する需要の高まりと研究開発の増加が、市場の成長を促進すると予想されます。

市場力学

治療の進歩が予測期間中の片頭痛治療薬市場の成長を促進すると予想されます

新薬や新しいドラッグデリバリーシステム（針注射、点鼻薬）の進歩などの治療の進歩が、予測期間中の世界の片頭痛治療薬市場の成長を促進すると予想されます。例えば、30分以内に投与すれば十分な性能を発揮する既存の治療薬と比較すると、これらの薬のいくつかは片頭痛の発作から2～4時間後に治療することができます。

臨床研究への資金提供の増加は、片頭痛治療薬市場に成長機会をもたらしています

主要な市場プレイヤーへの資金提供の増加は、今後数年間、世界の片頭痛治療薬市場の成長機会を確保しています。例えば、2022年8月、片頭痛ケアに集中したイスラエルベースのデジタル治療薬デザイナーであるTheranicaは、シリーズC資金で約4,500万米ドルを調達しました。

COVID-19の影響分析

COVID-19の分析には、Pre-COVIDシナリオ、COVIDシナリオ、Post-COVIDシナリオがあり、価格力学（パンデミック時およびパンデミック後の価格変動とCOVID前のシナリオとの比較）、需給スペクトル（取引制限、封鎖およびその後の問題による需要と供給のシフト）、政府の取り組み（政府機関による市場、セクター、産業の活性化に関する取り組み）、メーカーの戦略的取り組み（COVID問題を軽減するためのメーカーの取り組み）についても解説する予定です。

ロシア・ウクライナ紛争分析

ウクライナとロシアは、ともに国際的な臨床試験活動の広範な拠点です。ウクライナへの攻撃は、両国の採用予定地の失敗により、片頭痛治療薬を含む世界な医薬品開発の成果を弱体化させる可能性があります。軍事的対立による混乱は、片頭痛治療薬などを含むヘルスケアに大きな影響を与えます。

世界同時不況の影響分析

ヘルスケア業界も不況の影響を完全に受けないわけではありません。しかし、その本質的な性質から、他の業界よりもうまく対処しています。しかし、インフレ率が上昇を続ける中、景気後退の危機は市場を脅かしています。持続的な景気後退に対する緊張感の高まりは、今後数年間、市場に大きな影響を与える可能性があります。

人工知能の影響分析

2023年5月、仮想臨床試験プラットフォーム提供企業であるHealintは、日本の埼玉医科大学病院と提携し、片頭痛を検出するためにAIをどのように採用できるかを実験しました。この調査は、Healintのデータ用プラットフォーム「Migraine Buddy」によって推進されます。この調査では、AIがどのように患者を診断し、調査を行い、致命的な状況を突き止めることができるかを調査し、今後数年間の世界の片頭痛治療薬市場にプラスの影響を与えることが期待されます。

目次

第1章 調査手法とスコープ

  • 調査手法
  • 調査目的および調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

  • タイプ別スニペット
  • 投与経路別スニペット
  • 販売チャネル別スニペット

第4章 市場力学

  • 影響要因
    • 促進要因
      • 費用対効果の高い新製品の開発
      • 市場開拓
    • 抑制要因
      • 規制当局の厳しさ
    • 機会
    • 政府の取り組み
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • 法規制分析
  • 価格分析
  • 疫学分析
  • 特許分析

第6章 COVID-19の分析

  • COVID-19の分析
    • COVID-19の登場前シナリオ
    • 現在のCOVID-19のシナリオ
    • COVID-19後のシナリオ、または将来のシナリオ
  • COVID-19の中での価格・ダイナミクス
  • 需給スペクトル
  • パンデミック時の市場に関連する政府の取り組み
  • メーカー各社の戦略的取り組み
  • 結論

第7章 ロシア・ウクライナ紛争分析

第8章 世界同時不況の分析

第9章 人工知能の影響分析

第10章 タイプ別

  • 予防薬
  • 予防医学

第11章 投与経路別

  • 経口
  • 注射剤
  • その他

第12章 流通チャネル別

  • 病院内薬局
  • 小売薬局
  • オンライン薬局

第13章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第14章 競合情勢

  • 競合シナリオ
  • 市場シェア分析
  • M&A（合併・買収）分析

第15章 企業プロファイル

  • Abbott Laboratories
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展状況
  • AbbVie Inc
  • Allergan Plc.
  • AstraZeneca PLC.
  • Eisai Co., Ltd.
  • Endo International Plc.
  • GlaxoSmithKline Plc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Johnson & Johnson

第16章 付録

目次
Product Code: PH2530

Market Overview

The global migraine drugs market reached USD 4,035.8 million in 2022 and is projected to witness lucrative growth by reaching up to USD 9,791.1 million by 2030. The migraine drugs market is expected to exhibit a CAGR of 12.1% during the forecast period (2023-2030), owing to the increase in the preponderance of migraine globally and the increase in awareness regarding migraine and their therapy choices. Additionally, a rise in demand for secure and efficacious therapy and an increase in research and development is anticipated to promote the growth of the market.

Market Dynamics

The Treatment Advancements are Expected to Drive the Migraine Drugs Market Growth During the Forecast Period.

The treatment advancements such as the advancements in new drugs and new drug delivery systems (needle injections, nasal sprays) are expected to drive the global migraine drugs market growth during the forecast period. For example, a few of these medications can treat migraine 2-4 hours into an attack when compared to the pre-existing therapies that perform satisfactorily if administered within 30 minutes.

The Increasing Funding for Clinical Research is Providing Growth Opportunities for Migraine Drugs Market.

The growing funding to the key market players is ensuring growth opportunities for the global migraine drugs market in the upcoming years. For instance, in August 2022, Theranica, an Israel-based digital therapeutics designer concentrated on migraine care, raised around USD 45 million in Series C funding.

COVID-19 Impact Analysis

The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it to pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here).

Russia-Ukraine Conflict Analysis

Ukraine and Russia are both extensive bases for international clinical trial activities. The attack on Ukraine may cause an underpowering of global drug development outcomes including drugs for migraine with the failure of prospective recruitment locations for both nations. The turmoil and disorder induced by military confrontation have a significant influence over healthcare including migraine drugs and others.

Global Recession Impact Analysis

The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employing freezes during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. However, the danger of recession threatens the market as inflation persists increasing. The elevated extent of tension about the persistent recession could hold a substantial influence on the scleroderma market over the following few years.

Artificial Intelligence Impact Analysis

In May 2023, Healint, a virtual clinical trial platform-delivering company, partnered with the Saitama Medical University Hospital in Japan to experiment with how AI could be employed to detect migraines. The investigation is fueled by Healint's Migraine Buddy platform for data. The research will investigate how AI could diagnose patients, pick therapies and pinpoint possible fatal circumstances positively impacting the global migraine drugs market in the upcoming years.

Segment Analysis

The global migraine drugs market is segmented based on phase, design, indication, service, and region.

The Retail Pharmacy Segment is Estimated to Hold a 35% Share of the Global Market by 2030.

The majority of migraine preventive or abortive medications are intended for relieving the induced symptoms and averting or subsiding the migraine attack. These medications are primarily analgesics and OTC medicines that are easily available from retail pharmacies. Therefore, the retail pharmacy segment is estimated to hold a dominant share of the global migraine drugs market accounting for around 35.0% of the total market throughout the forecast period.

Geographical Analysis

Europe is Estimated to Hold the Second-largest Share of the Global Migraine Drugs Market During the Forecast Period.

Europe is estimated to hold around 28.2% of the total migraine drugs market owing to the high spending on migraine by European individuals and the efforts by various organizations to spread awareness about migraine in this region. For instance, according to a new article published in September 2022, at the recent Migraine Trust International Symposium, the world's longest-established headache medical conference, supporters gathered jointly to reach for enhanced guidelines for those impacted by migraine. Migraine persists to be a considerable public health issue across Europe costing European economies an assessed €55 billion yearly in immediate and indirect health care costs.

Competitive Landscape

The major global players in the market include: Allergen, Eisai, Ltd., AstraZeneca plc, Abbott Laboratories, Eisai Co., Ltd., Endo International Plc., GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc., and Johnson & Johnson among others.

Why Purchase the Report?

  • To visualize the global migraine drugs market segmentation based on type, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of migraine drugs market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global migraine drugs market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by Distribution Channel

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Development Of Various New Cost-Effective Products
      • 4.1.1.2. Market Developments
    • 4.1.2. Restraints
      • 4.1.2.1. Stringent Regulatory Authorities
    • 4.1.3. Opportunity
    • 4.1.4. Government Initiatives
    • 4.1.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Pricing Analysis
  • 5.4. Epidemiological Analysis
  • 5.5. Patent Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine Conflict Analysis

8. Global Recession Analysis

9. Artificial Intelligence Impact Analysis

10. By Type

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.1.2. Market Attractiveness Index, By Type
  • 10.2. Abortive Medicine
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Preventive Medicine

11. By Route of Administration

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.1.2. Market Attractiveness Index, By Route of Administration
  • 11.2. Oral *
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Injectable
  • 11.4. Others

12. By Distribution Channel

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.1.2. Market Attractiveness Index, By Distribution Channel
  • 12.2. Hospital Based Pharmacies
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Retail Pharmacies
  • 12.4. Online Pharmacies

13. By Region

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 13.1.2. Market Attractiveness Index, By Region
  • 13.2. North America
    • 13.2.1. Introduction
    • 13.2.2. Key Region-Specific Dynamics
    • 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.2.6.1. The U.S.
      • 13.2.6.2. Canada
      • 13.2.6.3. Mexico
  • 13.3. Europe
    • 13.3.1. Introduction
    • 13.3.2. Key Region-Specific Dynamics
    • 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.3.6.1. Germany
      • 13.3.6.2. The U.K.
      • 13.3.6.3. France
      • 13.3.6.4. Italy
      • 13.3.6.5. Spain
      • 13.3.6.6. Rest of Europe
  • 13.4. South America
    • 13.4.1. Introduction
    • 13.4.2. Key Region-Specific Dynamics
    • 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.4.6.1. Brazil
      • 13.4.6.2. Argentina
      • 13.4.6.3. Rest of South America
  • 13.5. Asia-Pacific
    • 13.5.1. Introduction
    • 13.5.2. Key Region-Specific Dynamics
    • 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.5.6.1. China
      • 13.5.6.2. India
      • 13.5.6.3. Japan
      • 13.5.6.4. Australia
      • 13.5.6.5. Rest of Asia-Pacific
  • 13.6. Middle East and Africa
    • 13.6.1. Introduction
    • 13.6.2. Key Region-Specific Dynamics
    • 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

14. Competitive Landscape

  • 14.1. Competitive Scenario
  • 14.2. Market Share Analysis
  • 14.3. Mergers and Acquisitions Analysis

15. Company Profiles

  • 15.1. Abbott Laboratories
    • 15.1.1. Company Overview
    • 15.1.2. Type Portfolio and Description
    • 15.1.3. Financial Overview
    • 15.1.4. Key Developments
  • 15.2. AbbVie Inc
  • 15.3. Allergan Plc.
  • 15.4. AstraZeneca PLC.
  • 15.5. Eisai Co., Ltd.
  • 15.6. Endo International Plc.
  • 15.7. GlaxoSmithKline Plc.
  • 15.8. Merck & Co., Inc.
  • 15.9. Pfizer Inc.
  • 15.10. Johnson & Johnson

LIST NOT EXHAUSTIVE

16. Appendix

  • 16.1. About Us and Services
  • 16.2. Contact Us